Study Details
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinicaltrials.gov ID
Astellas Study ID
8951-CL-0302
EudraCT ID
2018-000519-26
Condition
Stomach or Esophageal Cancer
Phase
Phase 3
Age
18 Years - N/A
Sex
Female & Male
Product
zolbetuximab
Type
Interventional
Trial Dates
Nov 2018 - Apr 2025
Masking
Double (Participant, Investigator)
Enrollment number
507
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site KR82013
Seoul, Republic of Korea
Site ES34010
Barcelona, Spain
Site HR38503
Zagreb, Croatia
Site GR30006
Thessaloniki, Greece
Prisma Health Cancer Institute
Boiling Springs, United States, 29316
Site RO40001
Iasi, Romania
Site KR82015
Seoul, Republic of Korea
Site GB44004
Cardiff, United Kingdom
Site PT35101
Setubal, Portugal
Site PT35109
Braga, Portugal
Site TR90002
Istanbul, Turkey
Site AR54008
Córdoba, Argentina
Site ES34009
Barcelona, Spain
Site ES34004
Pamplona, Spain
Utah Cancer Specialist
Salt Lake City, United States, 84106
Site JP81004
Kita-gun, Japan
Site ES34011
Malaga, Spain
Site JP81011
Tsukiji, Japan
Site CN86015
Fuzhou, China
Site CN86030
Xiamen, China
University of Texas Southwestern Medical Center
Dallas, United States, 75390
Ochsner Clinic CCOP
New Orleans, United States, 70121
Site JP81002
Chiba, Japan
Site GB44005
Northwood, United Kingdom
Site CN86026
Shantou, China
Site ES34005
Coruña, Spain
Site PT35111
Guimaraes, Portugal
Site PT35105
Porto, Portugal
Site GB44001
London, United Kingdom
Site TH66001
Muang, Thailand
Site ES34007
Valencia, Spain
Site AR54001
San Miguel De Tucuman, Argentina
Site RO40005
Cluj-Napoca, Romania
Site CN86037
Fuzhou, China
Site AR54003
Viedma, Argentina
Site JP81006
Kashiwa, Japan
Site CA15004
Calgary, Canada
Site CN86038
Linyi, China
Site KR82008
Jeollanam-do, Republic of Korea
Site TW88602
Kaohsiung, Taiwan, Province of China
Site CN86001
Guangzhou, China
Site CN86016
Nanjing, China
Site TH66003
Muang, Thailand
Site CN86018
Beijing, China
Site JP81001
Yokohama, Japan
Site CN86021
Changzhou, China
Site AR54004
San Miguel de Tucumán, Argentina
Site GR30004
Heraklion, Greece
Site MY60003
Kuala Lumpur, Malaysia
Site KR82007
Gyeonggi-do, Republic of Korea
Site CN86029
Changsha, China
Site RO40010
Timisoara, Romania
Site KR82012
Seoul, Republic of Korea
Site TR90012
Bornova, Turkey
Site CN86042
Guangzhou, China
Site CN86036
Hangzhou, China
Site MY60004
Kota Kinabalu, Malaysia
Site TH66011
Laksi, Thailand
Site TR90004
Balcali, Turkey
University of Kansas Cancer Center and Medical Pavilion
Fairway, United States, 66205
Site TW88605
Tianan, Taiwan, Province of China
Site CN86053
Changchun, China
Site CN86044
Baoding, China
Weill Cornell Medical College (WCMC)
New York, United States, 10021
Site CN86011
Xuzhou, China
Site CN86047
Shenyang, China
Site AT43002
Salzburg, Austria
Site NL31004
Groningen, Netherlands
Site TH66008
Watthana, Thailand
Site KR82014
Incheon, Republic of Korea
Site CN86007
Hangzhou, China
Site TH66007
Bangkok, Thailand
Site TR90010
Istanbul, Turkey
Site PT35108
Porto, Portugal
Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology
Houston, United States, 77030
Site HR38504
Osijek, Croatia
Site CN86027
Suzhou, China
Site TR90007
Konya, Turkey
Site CN86005
Wuhan, China
Site IE35301
Dublin, Ireland
Site ES34002
Madrid, Spain
Site ES34001
Elche, Spain
Site TH66009
Bangkok, Thailand
Site GR30005
Neo Faliro, Piraeus, Greece
Site KR82003
Seoul, Republic of Korea
Site ES34006
Barcelona, Spain
Site RO40008
Timisoara, Romania
Site TR90008
Pendik, Turkey
Site RO40003
Craiova, Romania
Site RO40006
Iasi, Romania
Site CN86025
Bengbu, China
Site CA15003
Chicoutimi, Canada
Site JP81012
Koto-ku, Japan
Site TH66002
Bangkok, Thailand
Site CN86046
Wuxi, China
Site JP81005
Utsunomiya, Japan
Site CN86024
Zhengzhou, China
Mercy Clinic Oncology and Hematology
Oklahoma City, United States, 73120
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, United States, 90033
Site CN86002
Changchun, China
Site GR30003
Larissa, Greece
Site CA15002
Rimouski, Canada
Site RO40002
Bucharest, Romania
Site CN86039
Chengdu, China
Site KR82002
Daegu, Republic of Korea
Site ES34012
Valencia, Spain
Site GR30002
Thessaloniki, Greece
Site ES34003
Madrid, Spain
Site TH66004
Songkla, Thailand
Site PT35110
Coimbra, Portugal
Site AR54009
Buenos Aires, Argentina
Site CN86031
Urumchi, China
Site GR30007
Rio Patras, Greece
Site RO40007
Cluj-Napoca, Romania
Parkland Hospital
Dallas, United States, 75390
Site TR90015
Istanbul, Turkey
Site JP81009
Matsuyama, Japan
Site AT43004
Vienna, Austria
Site GB44002
Bristol, United Kingdom
Site MY60002
Kuala Lumpur, Malaysia
Site JP81007
Fukuoka-shi, Japan
Site PT35102
Lisboa, Portugal
Site CN86017
Shijiazhuang, China
Site PT35104
Santa Maria da Feira, Portugal
Site PT35107
Vila Real, Portugal
Site CN86028
Guangzhou, China
Site CN86009
Tianjin, China
Site IE35302
Dublin, Ireland
Site JP81003
Kawasaki, Japan
Site PT35106
Lisboa, Portugal
Site TH66005
Bangkok, Thailand
Site KR82006
Goyang-si, Republic of Korea
New Mexico Oncology Hematology
Albuquerque, United States, 87109
Site TW88603
Taichung, Taiwan, Province of China
Site CN86043
Hengyang, China
Site TH66010
Pathumwan, Thailand
Site CN86014
Shanghai, China
Site CA15001
Vancouver, Canada
Site KR82009
Suwon, Republic of Korea
Site ES34013
Madrid, Spain
Site TR90013
Konyaalti, Turkey
Site HR38501
Varazdin, Croatia
Site CN86032
Haikou, China
Site RO40009
Bucharest, Romania
Site CN86049
Changchun, China
Site KR82010
Jeonju-si, Republic of Korea
Site CN86033
Xiangyang, China
Site JP81008
Akashi, Japan
Site CN86034
Fuzhou, China
Site TH66006
Pathumthani, Thailand
Site NL31003
Tilburg, Netherlands
Site GR30001
Athens, Greece
Site CN86004
Wuhan, China
Site MY60005
Kuala Lumpur, Malaysia
Site CN86045
Nanning, China
Site CN86050
Beijing, China
Site KR82001
Seoul, Republic of Korea
Site CN86013
Xi'an, China
Site TR90001
Bursa, Turkey
Site MY60001
Georgetown, Malaysia
Pacific Cancer Care
Monterey, United States, 93940
Site RO40004
Floresti, Romania
Site HR38502
Zagreb, Croatia
Site CN86051
Haebrin, China
Site ES34008
Madrid, Spain
Site CN86048
Jinzhou, China
Site CN86012
Zhengzhou, China
Site TR90003
Atakum, Turkey
Site CN86040
Tianjin, China
Site TW88604
Taipei, Taiwan, Province of China
Site TR90011
Malatya, Turkey
Site KR82011
Seongnam-si, Republic of Korea
Site JP81010
Suita, Japan
Site CN86054
Dalian, China
Site AR54006
Pergamino, Argentina
Montefiore Medical Center (MMC)
The Bronx, United States, 10467
Site CN86035
Beijing, China
Site CN86052
Dalian, China
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
